Cigna Group (NYSE:CI) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Cigna Group (NYSE:CI) released its quarterly earnings data on Thursday. The health services provider reported $7.78 EPS for the quarter, beating analysts’ consensus estimates of $7.60 by $0.18, Zacks reports. Cigna Group had a net margin of 2.26% and a return on equity of 19.75%. The company had revenue of $70.04 billion during the quarter, compared to the consensus estimate of $70.14 billion. During the same quarter in the prior year, the firm earned $7.20 EPS. Cigna Group’s quarterly revenue was up 6.7% on a year-over-year basis. Cigna Group updated its FY 2026 guidance to 30.450- EPS.

Here are the key takeaways from Cigna Group’s conference call:

• Second-quarter results exceeded expectations: revenue reached $71.7 billion and adjusted EPS was $7.78, prompting Cigna to raise its 2026 adjusted EPS outlook to at least $30.45.
• Evernorth Specialty and Care Services adjusted earnings grew 22% year over year to $1.1 billion, supported by specialty utilization, faster biosimilar and specialty-generic adoption, operating efficiencies, and contributions from Shields Health Solutions.
• Cigna Healthcare adjusted earnings rose 17%, with membership growth in the U.S. employer business and slightly favorable medical-cost experience; full-year segment earnings guidance increased to at least $4.55 billion.
• Evernorth Pharmacy Benefit Services earnings declined to $609 million due to large contract renewals and investments in the rebate-free Signature model, while moderating GLP-1 utilization and faster biosimilar adoption are expected to pressure the business through the rest of 2026.
• Management continues investing in AI-enabled programs such as Pharmacy Forward and enhanced care coordination, which it says could cut specialty therapy-start times in half, support 20% more customers with complex needs, and reduce avoidable inpatient stays.

Cigna Group Trading Down 3.0%

Shares of NYSE CI traded down $8.91 during mid-day trading on Thursday, reaching $287.56. 2,320,486 shares of the company’s stock were exchanged, compared to its average volume of 1,498,951. The firm has a market capitalization of $76.07 billion, a price-to-earnings ratio of 9.59, a PEG ratio of 1.14 and a beta of 0.29. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.73 and a current ratio of 0.73. Cigna Group has a 52-week low of $239.51 and a 52-week high of $315.47. The company’s 50-day moving average is $286.75 and its 200-day moving average is $281.12.

Cigna Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a $1.56 dividend. This represents a $6.24 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 8th. Cigna Group’s dividend payout ratio is 26.45%.

More Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported second-quarter adjusted earnings of $7.78 per share, exceeding the $7.60 consensus estimate and rising from $7.20 a year earlier. Revenue increased approximately 7% year over year to about $71.7 billion. CI Q2 Earnings Beat Estimates on Cigna Healthcare Strength
• Positive Sentiment: The company raised its 2026 adjusted earnings outlook to at least $30.45 per share, slightly above the roughly $30.40 analyst consensus. Growth was broad-based, with Cigna Healthcare revenue up 9% and Evernorth Health Services revenue up 6% year over year. Cigna raises annual profit forecast on strength in health services unit
• Neutral Sentiment: Net income reached nearly $1.7 billion, or $6.29 per share, while adjusted operating income was $2.1 billion. The results indicate continued operating strength, although reported revenue was modestly below one estimate of $70.14 billion, depending on the company’s reporting measure used. The Cigna Group Reports Strong Second Quarter 2026 Results
• Negative Sentiment: Management expects lower growth in prescriptions for popular GLP-1 drugs, while higher pharmacy costs remain a concern. Those comments appear to be tempering the market’s reaction to the earnings beat and guidance increase. Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions

Insider Activity

In other news, CEO David Cordani sold 201,878 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $292.82, for a total value of $59,113,915.96. Following the sale, the chief executive officer directly owned 34,337 shares of the company’s stock, valued at approximately $10,054,560.34. The trade was a 85.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $298.61, for a total transaction of $268,450.39. Following the completion of the transaction, the chief accounting officer owned 2,368 shares in the company, valued at approximately $707,108.48. This represents a 27.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Cigna Group by 1.8% in the fourth quarter. State Street Corp now owns 12,339,250 shares of the health services provider’s stock valued at $3,396,132,000 after buying an additional 224,122 shares in the last quarter. Dodge & Cox boosted its holdings in Cigna Group by 19.7% during the 4th quarter. Dodge & Cox now owns 11,138,614 shares of the health services provider’s stock valued at $3,065,681,000 after acquiring an additional 1,833,389 shares during the period. GQG Partners LLC grew its position in Cigna Group by 14.3% in the 4th quarter. GQG Partners LLC now owns 7,763,295 shares of the health services provider’s stock valued at $2,136,699,000 after acquiring an additional 972,302 shares in the last quarter. Invesco Ltd. grew its position in Cigna Group by 27.4% in the 4th quarter. Invesco Ltd. now owns 2,421,775 shares of the health services provider’s stock valued at $666,545,000 after acquiring an additional 521,273 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Cigna Group by 1.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,325,173 shares of the health services provider’s stock worth $639,957,000 after purchasing an additional 23,202 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CI shares. Weiss Ratings restated a “hold (c)” rating on shares of Cigna Group in a research report on Monday, June 1st. Wells Fargo & Company boosted their price objective on Cigna Group from $300.00 to $305.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. UBS Group upped their target price on Cigna Group from $375.00 to $400.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 target price on shares of Cigna Group in a research note on Tuesday, June 16th. Finally, Jefferies Financial Group lowered their price target on shares of Cigna Group from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $338.80.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.